DCR :直肠内超声,MRI和粘膜完整性可以预测术前放化疗后中低位直肠癌的治疗反应

2018-07-19 MedSci MedSci原创

如果患者局部晚期直肠癌可以通过术前放化疗得到完全缓解那么他们可以通过观察和等待来决定下一步治疗方案,同时他们可以通过粘膜完整性,直肠内超声和直肠MRI用于评估临床完全反应;但是,这些方案的准确性仍然值得怀疑。因此本项前瞻性研究的目的是评估粘膜完整性,直肠内超声和直肠MRI的准确性,以判断是否预测化放疗后的临床完全反应。

背景:
如果患者局部晚期直肠癌可以通过术前放化疗得到完全缓解那么他们可以通过观察和等待来决定下一步治疗方案,同时他们可以通过粘膜完整性,直肠内超声和直肠MRI用于评估临床完全反应;但是,这些方案的准确性仍然值得怀疑。因此本项前瞻性研究的目的是评估粘膜完整性,直肠内超声和直肠MRI的准确性,以判断是否预测化放疗后的临床完全反应。

方法:
本项研究纳入了2014年5月至2016年12月期间通过活检诊断为中低位直肠癌的患者。所有入组患者在术前化放疗6至7周后进行直肠内超声和直肠MRI检查,然后患者接受基于全直肠系膜切除原则的根治性手术。通过病理检查比较直肠超声和直肠MRI术前肿瘤分期与术后分期。计算每种评估方法的灵敏度,特异性和准确性。

结果:
共有124名患者参加了本研究,术后病理学显示20名患者(16.13%)达到完全缓解(T0N0)。粘膜完整性,直肠内超声和MRI预测临床完全反应的敏感性为25%。粘膜完整性,直肠内超声和MRI的特异性分别为94.23%,93.90%和93.27%。每种2种或所有3种方法的组合并未提高准确性。回归分析显示,这些方法均无法预测术后肿瘤分期。

结论:
单一方法和联合粘膜完整性,直肠内超声和直肠MRI与术后病理检查结果的相关性较差。与新辅助治疗后的根治性手术相比,基于这些方法的观察和等待方法可能不是一种合适的治疗策略。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2006726, encodeId=734d2006e26c9, content=<a href='/topic/show?id=99ff45888bc' target=_blank style='color:#2F92EE;'>#完整性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45888, encryptionId=99ff45888bc, topicName=完整性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Tue Apr 16 08:29:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690996, encodeId=922316909963d, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Sun Jun 23 13:29:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287926, encodeId=3cce128e9262e, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Sat Jul 21 04:29:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332847, encodeId=f84533284e78, content=好好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Fri Jul 20 06:44:31 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332739, encodeId=3f4f332e3914, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Jul 19 15:47:47 CST 2018, time=2018-07-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2006726, encodeId=734d2006e26c9, content=<a href='/topic/show?id=99ff45888bc' target=_blank style='color:#2F92EE;'>#完整性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45888, encryptionId=99ff45888bc, topicName=完整性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Tue Apr 16 08:29:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690996, encodeId=922316909963d, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Sun Jun 23 13:29:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287926, encodeId=3cce128e9262e, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Sat Jul 21 04:29:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332847, encodeId=f84533284e78, content=好好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Fri Jul 20 06:44:31 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332739, encodeId=3f4f332e3914, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Jul 19 15:47:47 CST 2018, time=2018-07-19, status=1, ipAttribution=)]
    2019-06-23 guoyibin
  3. [GetPortalCommentsPageByObjectIdResponse(id=2006726, encodeId=734d2006e26c9, content=<a href='/topic/show?id=99ff45888bc' target=_blank style='color:#2F92EE;'>#完整性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45888, encryptionId=99ff45888bc, topicName=完整性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Tue Apr 16 08:29:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690996, encodeId=922316909963d, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Sun Jun 23 13:29:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287926, encodeId=3cce128e9262e, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Sat Jul 21 04:29:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332847, encodeId=f84533284e78, content=好好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Fri Jul 20 06:44:31 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332739, encodeId=3f4f332e3914, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Jul 19 15:47:47 CST 2018, time=2018-07-19, status=1, ipAttribution=)]
    2018-07-21 yzh399
  4. [GetPortalCommentsPageByObjectIdResponse(id=2006726, encodeId=734d2006e26c9, content=<a href='/topic/show?id=99ff45888bc' target=_blank style='color:#2F92EE;'>#完整性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45888, encryptionId=99ff45888bc, topicName=完整性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Tue Apr 16 08:29:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690996, encodeId=922316909963d, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Sun Jun 23 13:29:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287926, encodeId=3cce128e9262e, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Sat Jul 21 04:29:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332847, encodeId=f84533284e78, content=好好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Fri Jul 20 06:44:31 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332739, encodeId=3f4f332e3914, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Jul 19 15:47:47 CST 2018, time=2018-07-19, status=1, ipAttribution=)]
    2018-07-20 张新亮1853311252142e2fm

    好好文献学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2006726, encodeId=734d2006e26c9, content=<a href='/topic/show?id=99ff45888bc' target=_blank style='color:#2F92EE;'>#完整性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45888, encryptionId=99ff45888bc, topicName=完整性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Tue Apr 16 08:29:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690996, encodeId=922316909963d, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Sun Jun 23 13:29:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287926, encodeId=3cce128e9262e, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Sat Jul 21 04:29:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332847, encodeId=f84533284e78, content=好好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Fri Jul 20 06:44:31 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332739, encodeId=3f4f332e3914, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Jul 19 15:47:47 CST 2018, time=2018-07-19, status=1, ipAttribution=)]
    2018-07-19 1ddf0692m34(暂无匿称)

    学习了,长知识

    0

相关资讯

J CLIN ONCOL:III期选择性试验中年龄对lenvatinib治疗放射性碘难治性分化型甲状腺癌疗效和安全性的影响

在lenvatinib治疗分化型甲状腺癌的研究中(E7o8o)中,lenvatinib与安慰剂相比, 显着延长了放射性碘难治性分化型甲状腺癌病人(RR-DTC)的无进展生存期(PFS)。预先设定的亚组分析研究了年龄对lenvatinib的疗效和安全性的影响。

J CLIN ONCOL:塞来考昔联合标准化疗对环氧合酶-2过表达的晚期非小细胞肺癌的III期试验

肿瘤环氧合酶-2(COX-2)过度表达与非小细胞肺癌(NSCLC)的不良预后相关。在癌症和白血病B组(CALGB)30203,研究人员发现选择性COX-2抑制剂塞来考昔联合化疗方案可以改善经免疫组织化学(IHC)证实的中到高表达COX-2的晚期NSCLC患者的无进展生存期和总生存期。

PLoS MED:BMI对帕金森发病的影响

在以前的报道中我们已经发现BMI指数偏高对于帕金森(PD)的发病有关,但是具体是保护性因素还是危险因素目前还没有定论。最近,有一项研究采用了孟德尔随机化(MR)设计探索了BMI与帕金森之间的因果关系。